Securities code: Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) securities abbreviation: Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) Announcement No.: 2022016 Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266)
Announcement on the progress of increasing shares held by the actual controller, some directors, senior managers and core managers of the company
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
Important content tips:
Basic information of the shareholding increase plan: Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) (hereinafter referred to as “the company”) the actual controller, some directors, senior managers and core managers, based on their confidence in the company’s future development and recognition of the company’s long-term investment value, plan to, Increase the company’s shares by means allowed by the trading system of Shanghai Stock Exchange (including but not limited to centralized bidding and block trading), with a total increase of no less than 18.8 million yuan and no more than 23.7 million yuan. For details, please refer to the website of Shanghai Stock Exchange (www.sse. Com. CN.) Announcement on the share increase plan of the actual controller, some directors, senior managers and core managers of the company (Announcement No.: 2022014).
Progress in the implementation of the shareholding increase plan: as of March 11, 2022, the shareholding increase subjects have accumulated 277777 shares of the company through centralized bidding through the trading system of Shanghai Stock Exchange, accounting for 0.1157% of the total share capital of the company. The total shareholding increase amount is RMB 10249500, accounting for 545188% of the lower limit of the shareholding increase plan, which has exceeded 50% of the lower limit of the shareholding increase plan, The share increase plan has not been implemented yet. The increase subject will continue to increase the shares of the company within the implementation time of the increase plan in accordance with the relevant increase plan.
There may be risks that the shareholding increase plan cannot be implemented due to changes in securities market conditions and policy factors. If the above-mentioned risk situations occur during the implementation of the shareholding increase plan, the company will timely perform the obligation of information disclosure.
1、 Basic information of the increased holding subject
(I) name of the increased shareholding entity: Mr. Zelin Sheng, the controlling shareholder, one of the actual controllers, chairman and general manager of the company, Ms. Lu Huiping, one of the actual controllers, director and executive deputy general manager, Mr. Jisheng Wu, director and deputy general manager, Mr. LV Binhua, deputy general manager, Mr. Junli Zhang, deputy general manager, Ms. Gao Qingping, deputy general manager and Secretary of the board of directors, Mr. Huang Gang, deputy general manager and financial director, Mr. Ding Wei, vice president of marketing, and Mr. Peng Jian, executive vice president of drug development and registration strategy.
(II) as of March 11, 2022, the shareholding of the above increased entities is as follows:
Sequence name shareholding quantity shareholding proportion No
1. Zelin Sheng directly holds 49852227 shares of the company and indirectly holds 110010 shares of the company through Kunshan 208176% (Sheng Zelin) and shanjing’ao
Directly holding 12586440 shares of the company through Ning
2. Lu Huiping, Bo zeao and Ningbo Jingchen indirectly hold 5.8603% shares of 1478233 of the company
3 Jisheng Wu directly holds 4000 shares of the company and indirectly holds 943888 shares of the company through Kunshan Jingao 0.3950% (Wu Jisheng)
Directly holding 8000 shares of the company through Kunshan Jing
4. Lv Bin Huaao and Ningbo zeao indirectly hold 1.6808% of 4025885 shares of the company
5 Junli Zhang directly holds 0.0025% of 6037 shares of the company (Zhang Junli)
Directly holding 6000 shares of the company, through Ningbo Ze
6 Gaoqing Pingao, Kunshan Jingao and Ningbo Jingchen indirectly hold 2.2053% 5286775 shares of the company
7 Huang Gang directly holds 7500 shares of the company and indirectly holds 897567 shares of the company through 0.3771% of Ningbo zeao
8 Ding Wei directly holds 8033 shares of the company and indirectly holds 1214349 shares of the company through 0.5093% of Ningbo Jingchen
9 Peng Jian directly holds 0.0007% of 1600 shares of the company
Note: 1. Kunshan Jingao refers to “Kunshan Jingao pharmaceutical technology partnership (limited partnership)”, Ningbo Jingchen refers to “Ningbo Jingchen investment partnership (limited partnership)”, and Ningbo zeao refers to “Ningbo zeao equity investment management partnership (limited partnership)”. 2. As of March 11, 2022, the actual controllers of the company, Mr. Zelin Sheng and Ms. Lu Huiping, controlled 84557967 shares of the company directly or indirectly, accounting for 35.23% of the total share capital of the company, including shares of Kunshan Jingao, Ningbo Jingchen and Ningbo zeao.
(III) in the 12 months before the disclosure of the shareholding increase plan, the above-mentioned shareholding increase subjects have not disclosed the shareholding increase plan.
2、 Main contents of the shareholding increase plan
For details, please refer to the website of Shanghai Stock Exchange (www.sse. Com. CN.) Announcement on the share increase plan of the actual controller, some directors, senior managers and core managers of the company (Announcement No.: 2022014).
3、 Implementation progress of shareholding increase plan
As of March 11, 2022, the increase subjects have accumulated 277777 shares of the company through centralized bidding through the trading system of Shanghai Stock Exchange, accounting for 0.1157% of the total share capital of the company. The total increase amount is RMB 10249500, accounting for 545188% of the lower limit of the current increase plan, which has exceeded 50% of the lower limit of the current increase plan, The share increase plan has not been implemented yet.
The increase subject will continue to increase the shares of the company within the implementation time of the increase plan in accordance with the relevant increase plan. The details are as follows:
Xu name proposed increase amount increased amount increased number of shares increased (10000 yuan) (10000 yuan) (shares)
1 Zelin Sheng 10001100 793.88215607 (Sheng Zelin)
2 Lu Huiping 200250 78.2821000
3 Jisheng Wu 100150 14.394000 (Wu Jisheng)
4 LV Binhua 100150 29.208000
5 Junli Zhang 100150 21.626037 (Zhang Junli)
6 Gao Qingping 100150 21.956000
7 Huang Gang 80-120 29.777500
8 Ding Wei 100150 29.998033
9 Peng Jian 100150 5.861600
Total 18802370 102495277777
Note: the discrepancy between the total in the above table and the mantissa of the sum of the sub item values is caused by rounding.
4、 Uncertainty risk of the implementation of the shareholding increase plan
There may be risks that the shareholding increase plan cannot be implemented due to changes in securities market conditions and policy factors. If the above-mentioned risk situations occur during the implementation of the shareholding increase plan, the company will timely perform the obligation of information disclosure.
5、 Other instructions
(I) the implementation of this share increase plan will not lead to the distribution of shares of the company not meeting the listing conditions, the change of the controlling shareholders and actual controllers of the company, and the impact on the corporate governance structure and sustainable operation.
(II) in the process of implementing the share increase plan, the increase subject will abide by the relevant provisions of China Securities Regulatory Commission and Shanghai Stock Exchange on changes in equity of listed companies and sensitive periods of stock trading. (III) the company will continue to pay attention to the progress of this shareholding increase plan and fulfill the obligation of information disclosure in a timely manner in accordance with the provisions of relevant laws, administrative regulations, departmental rules and normative documents, such as the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the measures for the administration of the acquisition of listed companies, the Listing Rules of the science and Innovation Board of Shanghai Stock Exchange and so on.
It is hereby announced.
Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) board of directors March 14, 2022
